» Articles » PMID: 39523097

[Aumolertinib Combined with Anlotinib Inhibits Proliferation of Non-small Cell Lung Cancer Cells by Down-regulating the PI3K/AKT Pathway]

Overview
Specialty General Medicine
Date 2024 Nov 10
PMID 39523097
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the inhibitory effect of aumolertinib combined with anlotinib on proliferation of non-small cell lung cancer (NSCLC) cells.

Methods: CCK-8 assay, colony formation assay, and flow cytometry were used to assess the effect of different concentrations of aumolertinib or anlotinib on proliferation, survival, and apoptosis of PC-9 and HCC827 cells, and their synergistic effect was evaluated using the SynergyFinder model. In PC-9 and HCC827 cells treated with aumolertinib combined with anlotinib, the changes in cell invasion and migration abilities were assessed with Transwell assay, and the expressions of apoptosis- and invasion/migration-related proteins (Bax, Bcl-2, E-cadherin, vimentin, MMP2, and MMP9) and the key PI3K-Akt pathway proteins were detected using Western blotting.

Results: In PC-9 cells, the IC50 of aumolertinib and anlotinib was 1.701 μmol/L and 4.979 μmol/L, respectively, with a synergy score (ZIP) of 19.112; in HCC827 cells, their IC50 was 2.961 μmol/L and 7.934 μmol/L, respectively, with a ZIP of 12.325. Compared with aumolertinib and anlotinib used alone, their combined treatment more strongly inhibited the proliferation and survival, enhanced apoptosis and suppressed invasion and migration abilities of PC-9 and HCC827 cells. Western blotting showed that in both PC-9 and HCC827 cells, the combined treatment significantly upregulated the expressions of E-cadherin and Bax proteins, downregulated the expressions of Bcl-2, vimentin, MMP2, and MMP9 proteins, and reduced phosphorylation levels of PI3K and Akt.

Conclusion: Aumolertinib combined with anlotinib can effectively inhibit NSCLC cell proliferation by downregulating the PI3K-Akt pathway, suggesting a potentially new option for NSCLC treatment.

References
1.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

2.
Lv Y, Du T, Ji M, Wang C, Lin S, Xue N . A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. J Drug Target. 2018; 27(4):451-459. DOI: 10.1080/1061186X.2018.1542533. View

3.
Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P . Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res. 2019; 38(1):71. PMC: 6373028. DOI: 10.1186/s13046-019-1093-3. View

4.
Kim S, Seung B, Cho S, Lim H, Bae M, Sur J . Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor. Animals (Basel). 2021; 11(7). PMC: 8300234. DOI: 10.3390/ani11072079. View

5.
He J, Huang Z, Han L, Gong Y, Xie C . Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). Int J Oncol. 2021; 59(5). PMC: 8562388. DOI: 10.3892/ijo.2021.5270. View